Myelodysplastic Syndromes
August 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.
Authors:Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, Del Rey M, Insunza A, Tormo M, Diez-Campelo M, Xicoy B, Salido E, Sanchez-Del-Real J, Arenillas L, Florensa L, Luno E, Del Canizo C, Sanz GF, Maria Hernandez-Rivas J
Institution:Department of Hematology, Hospital Universitario de Leon, Leon, Spain.; Institute of Biomedicine (IBIOMED, Leon), Leon, Spain.; Unidad de Diagnostico Molecular y Celular del Cancer, IBSAL, IBMCC-Centro de Investigacion del Cancer (USAL-CSIC), Salamanca, Spain.; Department of Blood Transfusion, Hospital Clinic i Provincial, Barcelona, Spain.; Department of Hematology, Hospital del Mar, Barcelona, Spain.
Journal:Am J Hematol. 2017 Sep;92(9):E534-E541. doi: 10.1002/ajh.24813. Epub 2017 Jul 19.

2:Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
Authors:Heuser M, Gabdoulline R, Loffeld P, Dobbernack V, Kreimeyer H, Pankratz M, Flintrop M, Liebich A, Klesse S, Panagiota V, Stadler M, Wichmann M, Shahswar R, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Geffers R, Schlegelberger B, Gohring G, Kreipe HH, Germing U, Ganser A, Kroger N, Koenecke C, Thol F
Institution:Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625, Hannover, Germany. heuser.michael@mh-hannover.de.; Medizinische Klinik und Poliklinik I, Universtitatsklinikum Carl Gustav Carus, Dresden, Germany.; Klinik fur Hamatologie, Onkologie und Klinische Immunologie, Heinrich Heine University, Dusseldorf, Germany.; Helmholtz Centre for Infection Research, Braunschweig, Germany.; Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
Journal:Ann Hematol. 2017 Aug;96(8):1361-1372. doi: 10.1007/s00277-017-3027-5. Epub 2017 Jun 13.

3:Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Authors:Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A
Institution:Scientific Direction, IRCCS-CROB, 'Referral Cancer Centre of Basilicata', Rionero In Vulture (Pz), Italy.; Haematology, Department of Biomedicine and Prevention, 'Tor Vergata' University, Rome, Italy.; Laboratory of Pre-clinical and Translational Research, IRCCS-CROB, 'Referral Cancer Centre of Basilicata', Rionero In Vulture (Pz), Italy.; Haematology Clinic, Department of Clinic and Molecular Sciences, 'Universita Politecnica delle Marche', Ancona, Italy.; 'Seragnoli Institute of Haematology', University School of Medicine, Bologna, Italy.
Journal:Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17.

4:Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Authors:Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME
Institution:Bart L. Scott and H. Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcelo C. Pasquini, Brent R. Logan, Mehdi Hamadani, and Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; Juan Wu and Adam M. Mendizabal, Emmes Corporation, Rockville, MD; Steven M. Devine, Ohio State University Comprehensive Cancer Center, Columbus, OH; David L. Porter, University of Pennsylvania, Philadelphia, PA; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Erica D. Warlick, University of Minnesota, Minneapolis; Jennifer Le-Rademacher, Mayo Clinic, Rochester, MN; Hugo F. Fernandez, Moffitt Cancer Center, Tampa, FL; Edwin P. Alyea, Dana Farber Cancer Institute, Boston, MA; Asad Bashey, Northside Hospital Cancer Institute, Atlanta, GA; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Nancy L. Geller and Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda, MD; and Mitchell E. Horwitz, Duke University, Durham, NC.
Journal:J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.

5:An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.
Authors:Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G
Institution:Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Texas, USA.; Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Texas, USA.; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Texas, USA.
Journal:Am J Hematol. 2017 Jul;92(7):674-682. doi: 10.1002/ajh.24746. Epub 2017 Jun 9.

6:Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Authors:Park S, Hamel JF, Toma A, Kelaidi C, Thepot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Gotze K, Muller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P
Institution:Sophie Park, Centre Hospitalier Universitaire (CHU) Grenoble Alpes, Universite Grenoble Alpes, Grenoble; Jean-Francois Hamel and Sylvain Thepot, CHU d'Angers; Sylvain Thepot, Universite d'Angers, Institut National de la Sante et de la Recherche Medicale, Unite 1232, and LabEx IGO, Angers; Andrea Toma, CHU Henri Mondor, Assistance Publique Hopitaux de Paris (AP-HP), Universite Paris-Est Creteil; Rosa Sapena and Pierre Fenaux, CHU Saint Louis, AP-HP, Universite Paris X; Francois Dreyfus, CHU Cochin, AP-HP, Universite Paris V, Paris; Charikleia Kelaidi, CHU Avicenne, Avicenne; Odile Beyne-Rauzy, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Aspasia Stamatoullas, Centre Henri Becquerel, Rouen; Agnes Guerci-Bresler, CHU Nancy, Nancy; Dominique Bordessoule, CHU Dupuytren, Limoges; Pascale Cony-Makhoul, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy; Stephane Cheze, CHU de Caen, Caen; Eric Wattel, Centre Hospitalier Lyon-Sud, Pierre Benite, Lyon; Christian Rose, Universite Catholique de Lille, Lille; Norbert Vey, Institut Paoli-Calmettes Marseille, Marseille, France; Maria Diez Campelo, Hospital Universitario de Salamanca, Salamanca; Teresa Bernal, Hospital Central de Asturias, Oviedo; Fernando Ramos, Hospital de Leon, Leon; Marisa Calabuig, Hospital Clinico de Valencia; Guillermo F. Sanz, Hospital Universitario y Politecnico La Fe, Valencia, Spain; Valeria Santini and Alessandro Sanna, Azienda Ospedaliero Universitaria (AOU) Careggi and University of Florence, Florence; Enrico Balleari, Istituto di Ricovero e Cura a Carattere Scientifico AOU San Martino di Genova, Genova; Daniela Gioia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Dario Ferrero, Universita degli Studi di Torino; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Torino; Giovanni Cametti, Ospedale Maggiore di Chieri, Chieri; Fabrizio Pane, Universita Federico II, Napoli, Italy; Mikkael A. Sekeres and Jaime Fensterl, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Rami Komrokji, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Gail J. Roboz, Weill Medical College of Cornell University, New York, NY; Jennifer Kaivers and Ulrich Germing, University of Dusseldorf, Dusseldorf; Katharina Gotze and Catharina Muller-Thomas, Universitat Munchen, Munchen, Germany; and Ioannis Kotsianidis, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
Journal:J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.

7:Iron chelation therapy in low risk myelodysplastic syndrome.
Authors:Killick SB
Institution:Department of Haematology, Royal Bournemouth Hospital NHS Foundation Trust, Bournemouth, UK.
Journal:Br J Haematol. 2017 May;177(3):375-387. doi: 10.1111/bjh.14602. Epub 2017 Mar 16.

8:Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Authors:Stahl M, Zeidan AM
Institution:a Section of Hematology, Department of Internal Medicine, Section of Hematology, Yale University and the Yale Comprehensive Cancer Center , Yale University School of Medicine , New Haven , CT , USA.
Journal:Expert Rev Hematol. 2017 Apr;10(4):345-364. doi: 10.1080/17474086.2017.1297704. Epub 2017 Mar 9.

9:Self-reported sleep disturbance and survival in myelodysplastic syndromes.
Authors:Luskin MR, Cronin AM, Owens RL, DeAngelo DJ, Stone RM, Wadleigh M, Steensma DP, Abel GA
Institution:Dana-Farber Cancer Institute, Boston, MA, USA.
Journal:Br J Haematol. 2017 May;177(4):562-566. doi: 10.1111/bjh.14573. Epub 2017 Mar 8.

10:Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.
Authors:Lyons RM, Marek BJ, Paley C, Esposito J, McNamara K, Richards PD, DiBella N, Garcia-Manero G
Institution:Texas Oncology and US Oncology Research, 4411 Medical Drive, San Antonio, TX 78229, United States. Electronic address: roger.lyons@usoncology.com. 78503, United States. Electronic address: billie.marek@usoncology.com. United States. Electronic address: carole.paley@novartis.com. United States. Electronic address: jason.esposito@novartis.com. United States. Electronic address: katie.mcnamara@novartis.com. 24153, United States. Electronic address: paul.richards@usoncology.com. Street, Aurora, CO 80012, United States. Electronic address: nick.dibella@usoncology.com. TX 77030, United States. Electronic address: ggarciam@mdanderson.org.
Journal:Leuk Res. 2017 May;56:88-95. doi: 10.1016/j.leukres.2017.01.033. Epub 2017 Jan 31.

11:New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
Authors:Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A, Goh AS, Cortoos A, Huang V, Weill M, Merino Herranz R, Porter JB
Institution:American University of Beirut Medical Center, Beirut, Lebanon. Italy. Medical School, Patras, Greece. Italy.
Journal:Am J Hematol. 2017 May;92(5):420-428. doi: 10.1002/ajh.24668. Epub 2017 Feb 18.

12:Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
Authors:Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Houston, Texas. Maryland. Hospital, Detroit, Michigan. Houston, Texas.
Journal:Cancer. 2017 May 15;123(6):994-1002. doi: 10.1002/cncr.30533. Epub 2017 Jan 17.

13:Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myelodysplasies.
Authors:Ades L, Prebet T, Stamatoullas A, Recher C, Guieze R, Raffoux E, Bouabdallah K, Hunault M, Wattel E, Stalnikiewicz L, Toma A, Dombret H, Vey N, Sebert M, Gardin C, Chaffaut C, Chevret S, Fenaux P
Institution:Hopital St Louis, Assistance Publique-Hopitaux de Paris and Paris 7 University, Paris, France. du Haut-Leveque, Pessac, France. Paris, France. Paris, France pierre.fenaux@aphp.fr.
Journal:Haematologica. 2017 Apr;102(4):728-735. doi: 10.3324/haematol.2016.151894. Epub 2016 Dec 29.

14:Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect.
Authors:Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcarcel D
Institution:Hematopoietic Cell Transplant Program, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: gorti@vebron.net.
Journal:Exp Hematol. 2017 Apr;48:1-11. doi: 10.1016/j.exphem.2016.12.004. Epub 2016 Dec 24.

15:Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.
Authors:Del Corso L, Biale L, Parodi EL, Russo R, Filiberti R, Arboscello E
Institution:Internal Medicine, Department of Hematology and Oncology, IRCCS AOU San Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy. Corso Bramante 88, 10126, Turin, Italy. San Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy. San Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy. Genoa, Italy. Martino-IST, Largo R. Benzi, 10, 16132, Genoa, Italy. eleonora.arboscello@alice.it.
Journal:Int J Clin Oncol. 2017 Apr;22(2):380-386. doi: 10.1007/s10147-016-1042-5. Epub 2016 Oct 22.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: June 23, 2017
169 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS82629590

Coupon Expires: October 20, 2017



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.